Maxigen Biotech Inc (1783) - Total Assets
Based on the latest financial reports, Maxigen Biotech Inc (1783) holds total assets worth NT$2.03 Billion TWD (≈ $64.05 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Maxigen Biotech Inc - Total Assets Trend (2009–2025)
This chart illustrates how Maxigen Biotech Inc's total assets have evolved over time, based on quarterly financial data. Also see how much is Maxigen Biotech Inc worth for the company's overall valuation and market capitalisation.
Maxigen Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Maxigen Biotech Inc's total assets of NT$2.03 Billion consist of 59.2% current assets and 40.8% non-current assets. Review 1783 total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 30.4% |
| Accounts Receivable | NT$132.19 Million | 7.0% |
| Inventory | NT$99.19 Million | 5.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$730.00K | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Maxigen Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 1783 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maxigen Biotech Inc's current assets represent 59.2% of total assets in 2025, a decrease from 83.6% in 2009.
- Cash Position: Cash and equivalents constituted 30.4% of total assets in 2025, down from 54.4% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 13.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 7.0% of total assets.
Maxigen Biotech Inc Competitors by Total Assets
Key competitors of Maxigen Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Tinavi Medical Technologies Co Ltd
SHG:688277
|
China | CN¥1.64 Billion |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
Indonesia | Rp980.33 Billion |
|
Interojo Inc
KQ:119610
|
Korea | ₩252.22 Billion |
|
Daxor Corporation
NASDAQ:DXR
|
USA | $35.90 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
Maxigen Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.33 | 3.43 | 6.74 |
| Quick Ratio | 2.16 | 3.16 | 5.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$706.35 Million | NT$659.50 Million | NT$621.77 Million |
Maxigen Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Maxigen Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.25 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 19.6% |
| Total Assets | NT$1.89 Billion |
| Market Capitalization | $102.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Maxigen Biotech Inc's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Maxigen Biotech Inc's assets grew by 19.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Maxigen Biotech Inc (2009–2025)
The table below shows the annual total assets of Maxigen Biotech Inc from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.89 Billion ≈ $59.64 Million |
+19.63% |
| 2024-12-31 | NT$1.58 Billion ≈ $49.86 Million |
+5.99% |
| 2023-12-31 | NT$1.49 Billion ≈ $47.04 Million |
+3.13% |
| 2022-12-31 | NT$1.45 Billion ≈ $45.61 Million |
+14.43% |
| 2021-12-31 | NT$1.27 Billion ≈ $39.86 Million |
+32.28% |
| 2020-12-31 | NT$956.47 Million ≈ $30.13 Million |
-19.32% |
| 2019-12-31 | NT$1.19 Billion ≈ $37.35 Million |
+4.41% |
| 2018-12-31 | NT$1.14 Billion ≈ $35.77 Million |
+2.85% |
| 2017-12-31 | NT$1.10 Billion ≈ $34.78 Million |
+0.60% |
| 2016-12-31 | NT$1.10 Billion ≈ $34.57 Million |
-6.06% |
| 2015-12-31 | NT$1.17 Billion ≈ $36.81 Million |
+15.25% |
| 2014-12-31 | NT$1.01 Billion ≈ $31.94 Million |
-0.08% |
| 2013-12-31 | NT$1.01 Billion ≈ $31.96 Million |
+100.57% |
| 2012-12-31 | NT$505.76 Million ≈ $15.93 Million |
+3.93% |
| 2011-12-31 | NT$486.65 Million ≈ $15.33 Million |
+13.24% |
| 2010-12-31 | NT$429.76 Million ≈ $13.54 Million |
+25.09% |
| 2009-12-31 | NT$343.55 Million ≈ $10.82 Million |
-- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more